Engineered T-cell therapy shows efficacy in blood cancer

In simultaneously published papers from a group at the University of Pennsylvania, two out of three patients with advanced chronic lymphocytic leukemia (CLL) are reported to show complete remission after receiving engineered T cells that contain chimeric antigen receptors (CARs) specific for the B c...

Full description

Saved in:
Bibliographic Details
Published in:Nature biotechnology 2011-10, Vol.29 (10), p.853-854
Main Author: Frantz, Simon
Format: Article
Language:English
Subjects:
631/61/338
631/61/51/1844
631/92/436/108
692/699/67/1990
Agriculture
Animals
Antigens
Bioengineering
Bioinformatics
Biomedical and Life Sciences
Biomedical Engineering/Biotechnology
Biomedicine
Biotechnology
Cancer
Cellular biology
Cellular therapy
Clinical Trials as Topic
Drug Industry
Drug therapy
Health aspects
Hematologic Neoplasms - economics
Hematologic Neoplasms - immunology
Hematologic Neoplasms - therapy
Humans
Immunotherapy - adverse effects
Immunotherapy - economics
Immunotherapy - methods
Leukemia
Life Sciences
Mice
news
Physiological aspects
Precision Medicine
Receptors, Immunologic - immunology
Remission Induction
T cell receptors
T cells
T-Lymphocytes - immunology
Treatment Outcome
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In simultaneously published papers from a group at the University of Pennsylvania, two out of three patients with advanced chronic lymphocytic leukemia (CLL) are reported to show complete remission after receiving engineered T cells that contain chimeric antigen receptors (CARs) specific for the B cell-specific antigen CD19 fused to a hinge region, the costimulatory molecule 4-1BB and the T-cell receptor (TCR) CD3-ζ signaling domain. In terms of turning such cell therapies into products, however, the path to market remains unclear, particularly with concerns lingering over manufacturing, reimbursement and potential autoimmune complications arising from uncontrolled proliferation of the reintroduced cells.
ISSN:1087-0156
1546-1696
DOI:10.1038/nbt1011-853